Skip to main content
Final guidance on oral oxitriptan product compounding issued by FDA
7/15/2019

The FDA has issued final guidelines on compounding of oral oxitriptan drugs as a treatment for tetrahydrobiopterin deficiency, saying it doesn't plan to take regulatory action against pharmacists or physicians in such cases. The move follows a February final rule from the FDA, which included oxitriptan on a list of substances that cannot be used for compounding.

Full Story: